Invitae (NVTAQ)
(Delayed Data from OTC)
$0.00 USD
0.00 (33.33%)
Updated Jul 29, 2024 03:35 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NVTAQ 0.00 0.00(33.33%)
Will NVTAQ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVTAQ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVTAQ
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates
NVTAQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
Other News for NVTAQ
Invitae Launches Unlock? Behind the Seizure? Program for Pediatric Epilepsy Patients
Invitaeās April 2024 Bankruptcy Report Warns Investors
New Research Demonstrates the Importance of Genetic Testing for Many Cancers Not Currently Covered by Clinical Guidelines
Invitae Receives Court Approval for Sale to Labcorp
US Bankruptcy Court approves Invitae sale to Labcorp